SelectImmune Pharma holds digital investor meeting
SelectImmune Pharma is offering a digital investors’ meeting via Zoom, on Thursday September 23rd at 12.00 CET.
We welcome existing owners, other investors and interested parties to join. The meeting participants will be able to hear of the company developments and ask questions. These may be asked online in the meeting or be sent via e-mail to the addresses listed below.
The meeting will be held in Swedish.
Please use this link to participate:
https://us06web.zoom.us/j/88543060204?pwd=djUzRDh6VU9LQ1A1MGpVSzB2a1U4UT09
For written questions, please contact:
Catharina Svanborg
Chairman of the board SelectImmune Pharma AB
Phone: +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se
Ann Gidner
CEO SelectImmune Pharma AB
Phone: +46 768 17 14 14
E-mail: ann.gidner@selectImmune.com
SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.
Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world’s most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.